Etripamil Shows Promise for Recurring PSVT Episodes: ACC25 Presentation
Table of Contents
- 1. Etripamil Shows Promise for Recurring PSVT Episodes: ACC25 Presentation
- 2. Novel Nasal Spray Could Offer Relief for Paroxysmal Supraventricular Tachycardia Sufferers
- 3. Key Findings from the NODE-303 Trial
- 4. Etripamil: A Closer Look at the Science
- 5. What are the potential benefits of etripamil nasal spray for patients with PSVT?
- 6. Interview: dr. eleanor Vance on etripamil and PSVT Treatment
- 7. Interview with Dr. Eleanor Vance,Cardiologist
Published:
By Archyde News Desk
Novel Nasal Spray Could Offer Relief for Paroxysmal Supraventricular Tachycardia Sufferers
CHICAGO, IL—A potential breakthrough for the millions of Americans suffering from Paroxysmal Supraventricular Tachycardia (PSVT) is on the horizon. New data presented at the American college of Cardiology annual meeting (ACC.25), taking place March 29-31, 2025, in Chicago, Illinois, highlights the effectiveness of etripamil, an investigational self-administered nasal spray, in converting multiple PSVT episodes too normal sinus rhythm.
PSVT, characterized by sudden episodes of rapid heart rate, affects an estimated 1.7 million people in the U.S. Many experience debilitating symptoms like palpitations, dizziness, and shortness of breath, substantially impacting their quality of life. current treatments often involve trips to the emergency room or doctor’s office for intravenous medications.
The data,stemming from the NODE-303 trial,suggests that etripamil offers a significant advantage: the ability for patients to self-administer the medication at the onset of an episode,potentially avoiding costly and time-consuming medical interventions. The study, titled “Consistency and Predictiveness of Conversion Among Multiple Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) Treated with Etripamil: Outcomes from the NODE-303 trial,” was presented by Dr. James Ip, Associate Professor and Director of Cardiac Pacing and Implantable Devices, division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital.
“This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to restore normal sinus rhythm. Further, the data showed that conversion of earlier episodes was predictive of conversion in subsequent ones,”
David Bharucha, MD PhD FACC, Chief Medical Officer of milestone Pharmaceuticals
Dr.Bharucha further emphasized the potential benefits for patients, stating, “These new data support the possibility to use etripamil, if approved, for successive PSVT episodes underscoring a potentially positive impact on patients’ experience and quality of life, in line with Milestone’s commitment to providing a convenient and effective therapeutic option for PSVT.”
Key Findings from the NODE-303 Trial
The NODE-303 trial provides compelling evidence regarding the efficacy and consistency of etripamil in treating recurring PSVT episodes. Here’s a breakdown of the key takeaways:
- consistent Conversion: The study demonstrated that etripamil effectively converted multiple PSVT episodes back to normal sinus rhythm in participating patients.
- Predictive Conversion: A noteworthy finding was that the prosperous conversion of earlier episodes with etripamil was predictive of successful conversions in subsequent episodes. This suggests that patients who respond well to the initial treatment are likely to continue experiencing positive outcomes with repeated use.
These findings underscore the potential for etripamil to provide a reliable and consistent treatment option for individuals who experience frequent PSVT episodes, potentially reducing the need for repeated medical interventions.
Etripamil: A Closer Look at the Science
Etripamil is described as a novel calcium channel blocker nasal spray. calcium channel blockers are a class of medications that work by relaxing the heart muscle and blood vessels. This mechanism helps to slow down the heart rate and restore a normal rhythm in individuals experiencing PSVT.
The nasal spray formulation is particularly significant because it allows for rapid absorption of the drug into the bloodstream,which is crucial for quickly addressing the sudden onset of PSVT episodes. The self-administration aspect empowers patients to take control of their condition and manage their symptoms proactively.
One crucial aspect of the NODE-303 trial, as indicated in supplementary material, involves censoring for signal loss. the “+” symbol on the trial graph is an indication of this. This highlights a critical piece of data handling, where instances of signal loss where accounted for during the study’s 30-minute monitoring period. In practical terms, these censored data points represent cases where complete data collection was not possible. Careful management of these censored observations is important for avoiding bias and ensuring robust conclusions about how well etripamil helps convert PSVT episodes back to normal sinus rhythm.
the following data was provided in the original article, further illustrating its potential impact:
What are the potential benefits of etripamil nasal spray for patients with PSVT?
Interview: dr. eleanor Vance on etripamil and PSVT Treatment
By Archyde News Desk
Interview with Dr. Eleanor Vance,Cardiologist
Archyde News recently sat down with Dr. Eleanor Vance, a leading cardiologist specializing in arrhythmia, to discuss the latest developments in the treatment of Paroxysmal Supraventricular Tachycardia (PSVT), particularly focusing on the potential of etripamil nasal spray.
Archyde News: Dr. vance, thank you for joining us. Can you give us a general overview of PSVT and the challenges patients face?
Dr. Vance: Thank you for having me. PSVT, as you know, is characterized by sudden episodes of rapid heart rate. Patients ofen experience palpitations, dizziness, and shortness of breath.The main challenge is the critically important impact it has on their quality of life, frequently enough leading to frequent ER visits or doctor’s appointments for immediate treatment.
Archyde News: The NODE-303 trial results seem particularly promising. Can you elaborate on the importance of etripamil as a potential treatment?
Dr. Vance: Absolutely. Etripamil, a novel calcium channel blocker nasal spray, offers a significant advantage. The ability for patients to self-administer the medication at the onset of an episode represents a major shift. data from NODE-303 shows it can effectively convert multiple PSVT episodes back to a normal sinus rhythm.
Archyde News: The study mentions consistent conversion. That sounds very encouraging. Can you explain that in simple terms?
Dr. Vance: In simple terms, it means the medication worked consistently across multiple episodes in the patients. Moreover, if it worked well in the first few episodes, it was highly likely to work in subsequent ones. This is a crucial finding for patients.
Archyde News: The nasal spray aspect is captivating. How does this formulation contribute to its effectiveness?
Dr. Vance: The nasal spray allows for rapid absorption, which is vital. When a patient is experiencing a PSVT event, the prompt delivery of the medication is key to quickly restoring normal heart rhythm. Being able to self-administer gives patients a feeling of control.
Archyde News: The trial involved censoring for signal loss, where the “+” symbol on charts indicates this. What does this mean for interpreting the study’s findings?
Dr. Vance: Censoring for signal loss is a standard practice in clinical trials. It allows researchers to account for data inconsistencies like equipment malfunctions or unrecorded measurements during the 30 minutes observation time by properly using these factors during the analysis without bias. This significant step ensures conclusions drawn from the study are robust, and there is an accurate reflection of how and well etripamil restores normal sinus rhythm.
Archyde News: Considering the benefits, when might we expect etripamil to become available?
Dr. Vance: The timeline depends on regulatory approvals. With the promising results from phase 3 studies, if approved, we could see etripamil available, which would mean a shift in PSVT’s management for patients.
archyde News: Considering etripamil’s potential to offer a self-administered option, how do you foresee this affecting patients’ approaches to managing their PSVT?
Dr. vance: One great change is its capability to enhance patient independence. The new approach allows them to respond quickly, and for some people this is a welcome change from the customary reliance on doctors. This sense of patients taking control enables them to actively manage their health.
Archyde News: what message would you give to patients currently living with PSVT?
Dr. Vance: There’s significant hope on the horizon. Etripamil has shown very promising results. Further trials will clarify the treatment, but the progress is encouraging! self administration may greatly improve your quality of life.
Archyde News: Thank you, Dr.Vance, for sharing your insights with us.
Dr. Vance: my pleasure.
